Sleep is a fundamental phenomenon that helps maintain normal physiological processes. Conversely, sleep disorders, usually presented as insomnia, are a common public health problem that can lead to multiple pathophysiological changes in humans, including lipid metabolic abnormality. Interestingly, several previous studies have examined the potential relation of insomnia to metabolic syndrome and hyperlipidemia and found that insomnia was associated with elevated plasma cholesterol and triglyceride concentrations. This review summarizes evidence regarding the linkage between insomnia and lipid abnormalities. Moreover, the underlying physiologic mechanisms linking insomnia to lipid abnormalities are systemically discussed. Finally, issues with lipid-lowering drugs and the risk of insomnia are also presented. This knowledge can improve our understanding of the pathophysiological features of insomnia, which may help to prevent and treat insomnia-induced dyslipidemia clinically.
To explore the association between gamma-glutamyltransferase (GGT) and in-hospital heart failure (HF) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
A total of 412 patients diagnosed with STEMI and treated with primary PCI were included in our study. Univariate and multivariate logistic regression models were used to evaluate the association between GGT and the risk of in-hospital HF in STEMI patients. The receiver operating characteristic (ROC) curve was used to assess the accuracy of GGT in predicting in-hospital HF.
The incidence of HF after STEMI increased significantly with increasing GGT tertiles (the first, second, and third tertile groups were 7.97%, 14.49%, and 18.38%, respectively; p = 0.039). Multivariate logistic regression analysis revealed that the risk of HF in the second and third GGT tertile groups was 2.51 times greater (95% CI, 1.06–5.96) and 2.77 times greater (95% CI, 1.13–6.81), respectively, than that in the first GGT tertile group. Each 1-unit increase in the lnGGT level was related to a 1.88-fold increased risk of HF (odds ratio, OR, 1.88; 95% CI, 1.19–2.96; p = 0.007). Restricted cubic splines suggested a linear relationship between GGT and in-hospital HF (p for nonlinearity = 0.158). The area under the curve was 0.607 (95% CI, 0.558–0.654; p = 0.007) when GGT was used to predict in-hospital HF, with a sensitivity of 57.14% and a specificity of 64.04%. Moreover, the incidence of HF significantly increased in-hospital death risk (OR, 7.75; 95% CI, 1.87–32.12; p = 0.005).
GGT is positively associated with in-hospital HF and is an independent risk factor for in-hospital HF in STEMI patients.
There is a shortage of patients with hypertrophic cardiomyopathy (HCM) with concurrent coronary artery disease (CAD), and the influence of CAD on the prognosis of patients with HCM is uncertain. This real-world cohort study was conducted to evaluate the prognosis of patients with patients with CAD.
This cohort study of patients with HCM was conducted from May 2003 to September 2021. The total number of patients enrolled was 2167, and the mean follow-up period was 6.4 years (interquartile range 2.8–9.5 years). Sudden cardiac death (SCD), cardiovascular death, and all-cause mortality were assessed as outcomes. Using logistic regression, nine indicators were selected for 1:1 propensity score matching (PSM). Additionally, Kaplan–Meier survival curves and Cox proportional hazards regression analyses were used to assess the impact of CAD on the prognosis of patients with HCM.
During an average of 6.4 years of follow-up, of the 2167 patients enrolled, 446 (20.6%) died. The patients were classified into two groups: CAD (n = 480) and non-CAD (n = 1,687). After imputation of missing values using the mean and 1:1 propensity score matching, there was no difference in SCD (log-rank χ2 = 0.4, p = 0.540), cardiovascular death (log-rank χ2 = 0.1, p = 0.995) and all-cause mortality (log-rank χ2 = 0.1, p = 0.776) between the CAD and non-CAD groups. After imputation of missing values using the median and 1:1 propensity score matching, patients with and without CAD were not significantly different in terms of SCD (log-rank χ2 = 0.1, p = 0.948), cardiovascular death (log-rank χ2 = 0.1, p = 0.811), and all-cause mortality (log-rank χ2 = 0.5, p = 0.499). In the Cox analysis, CAD was not a significant independent predictor of SCD, cardiovascular death, or all-cause mortality in patients with HCM.
In this study, it was observed that there was no statistically significant disparity in mortality rates between patients diagnosed with HCM who concurrently had CAD and those who did not exhibit CAD. This finding underscores the notion that the presence of CAD did not exert a notable influence on the incidence of SCD, cardiovascular death, or all-cause mortality, thereby emphasizing the complexity and multifaceted nature of mortality risk factors in HCM patients.
Heart failure (HF) remains a global challenge with disappointing long-term outcomes. Malnutrition is prevalent in patients with HF and disrupts the equilibrium of immune and inflammatory responses, resulting in further deterioration of the HF. Novel indicators emerge as immune nutrition indices, including the prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), Controlling Nutritional Status (CONUT) score, and cholesterol-modified prognostic nutritional index (CPNI). This study examines the correlation between immune nutrition indices and all-cause and cardiovascular mortality in patients with HF.
The data source for this study was the National Health and Nutrition Examination Survey (NHANES). A total of 1232 participants with HF were included. Weighted Cox proportional hazards models were employed to assess the independent association of different immune nutrition indices with mortality risk, alongside subgroup analyses and Kaplan–Meier survival curves. Restricted cubic spline analysis was utilized to clarify the detailed association between immune nutrition indices and hazard ratio (HR). A time-dependent receiver operating characteristic curve analysis was conducted to assess the predictive ability.
After full adjustments, PNI is independently related to all-cause mortality (HR = 0.94, 95% CI: 0.92–0.97) and cardiovascular mortality (HR = 0.94, 95% CI: 0.90–0.99). CPNI, CONUT, and NLR also showed an independent association with the prognosis of HF. Time-dependent receiver operating characteristic curve analysis indicated that PNI exhibited the highest predictive power for mortality among the CPNI, CONUT, and NLR indexes.
Our study revealed that immune nutrition indicators, including CPNI, could predict all-cause mortality and cardiovascular mortality in the HF population. Compared with other indicators, PNI is the most effective predictor.
With a better understanding of the susceptibility to atrial fibrillation (AF) and the thrombogenicity of the left atrium, the concept of atrial cardiomyopathy (ACM) has emerged. The conventional viewpoint holds that AF-associated hemodynamic disturbances and thrombus formation in the left atrial appendage are the primary causes of cardiogenic embolism events. However, substantial evidence suggests that the relationship between cardiogenic embolism and AF is not so absolute, and that ACM may be an important, underestimated contributor to cardiogenic embolism events. Chronic inflammation, oxidative stress response, lipid accumulation, and fibrosis leading to ACM form the foundation for AF. Furthermore, persistent AF can exacerbate structural and electrical remodeling, as well as mechanical dysfunction of the atria, creating a vicious cycle. To date, the relationship between ACM, AF, and cardiogenic embolism remains unclear. Additionally, many clinicians still lack a comprehensive understanding of the concept of ACM. In this review, we first appraise the definition of ACM and subsequently summarize the noninvasive and feasible diagnostic techniques and criteria for clinical practice. These include imaging modalities such as echocardiography and cardiac magnetic resonance imaging, as well as electrocardiograms, serum biomarkers, and existing practical diagnostic criteria. Finally, we discuss management strategies for ACM, encompassing “upstream therapy” targeting risk factors, identifying and providing appropriate anticoagulation for patients at high risk of stroke/systemic embolism events, and controlling heart rhythm along with potential atrial substrate improvements.
Currently, there are no standardized guidelines for graft allocation in heart transplants (HTxs), particularly when considering organs from marginal donors and donors after cardiocirculatory arrest. This complexity highlights the need for an effective risk analysis tool for primary graft dysfunction (PGD), a severe complication in HTx. Existing score systems for predicting PGD lack superior predictive capability and are often too complex for routine clinical use. This study sought to develop a user-friendly score integrating variables from these systems to enhance the efficacy of the organ allocation process.
Severe PGD was defined as the need for mechanical circulatory support and/or death from an unknown etiology within the first 24 hours following HTx. We used a meta-analytical approach to create a derivation cohort to identify risk factors. We then applied a logistic regression analysis to generate an equation predicting severe PGD risk. We used our previous experience in HTx to create a validation cohort. Subsequently, we implemented the formula in a smartphone application.
The meta-analysis comprising six studies revealed a 10.5% ( 95% confidence interval (CI): 5.3–12.4) incidence rate of severe PGD and related 30-day mortality of 38.6%. Eleven risk factors were identified: female donors, female donor to male recipient, undersized donor, donor age, recipient on ventricular assist device support, recipient on amiodarone treatment, recipient with diabetes and renal dysfunction, re-sternotomy, graft ischemic time, and bypass time. An equation to predict the risk, including the 11 parameters (GREF-11), was created using logistic regression models and validated based on our experience involving 116 patients. In our series, 29 recipients (25%) required extracorporeal membrane oxygenation support within 24 hours post-HTx. The overall 30-day mortality was 4.3%, 3.4%, and 6.8% in the non-PGD and severe PGD groups, respectively. The area under the receiver operating characteristic (AU-ROC) curve of the model in the validation cohort was 0.804.
The GREF-11 application should offer HTx teams several benefits, including standardized risk assessment and bedside clinical decision support, thereby helping minimize the risk of severe PGD post-HTx.
To study the risk of cardiovascular disease (CVD) and other competing causes of death in older kidney cancer patients.
Data on older patients (aged 65 and above) diagnosed with kidney cancer between 1975 and 2018 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We delved into the distribution of CVD and other competing causes of death across the entire cohort and in various patient subgroups. The competing risk analysis was used to produce cumulative mortality curves based on cumulative mortality for the primary outcomes by follow-up period. Utilizing the standardized mortality ratios (SMRs) and absolute excess risks (AERs), we contrasted the risk of CVD and other competing causes of death in older kidney cancer patients to that observed in the general population.
The analysis included 29,349 older kidney cancer patients, of which included 4563 CVD deaths. As survival time extended, the proportion of non-cancer deaths increased in older kidney cancer patients, with CVD accounting for the largest share of non-cancer deaths. At 10–15 years after diagnosis, cumulative non-cancer mortality exceeded primary kidney cancer as the predominant cause of death, and cumulative CVD mortality is higher among all non-cancer causes. Older kidney cancer patients exhibited a greater risk of CVD and other non-cancer deaths than their counterparts in the general older population did (SMR: 1.38–2.81; AER: 1.1–143.69).
As survival time increases, the risk of non-cancer death in older kidney cancer patients gradually surpassed that of primary cancer, and CVD death accounted for the majority of non-cancer deaths. Among older kidney cancer patients, the risk of CVD mortality was higher than in the general population. Managing non-cancer deaths, especially CVD deaths, should be a focus in the care of older kidney cancer patients.
With the aging of the general population and the rise in surgical and transcatheter aortic valve replacement, there will be an increase in the prevalence of prosthetic aortic valves. Patients with prosthetic aortic valves can develop a wide range of unique pathologies compared to the general population. Accurate diagnosis is necessary in this population to generate a comprehensive treatment plan. Transthoracic echocardiography is often insufficient alone to diagnose many prosthetic valve pathologies. The integration of many imaging modalities, including transthoracic echocardiography, transesophageal echocardiography, cardiac computed tomography, cardiac magnetic resonance imaging, and nuclear imaging, is necessary to care for patients with prosthetic valves. The purpose of this review is to describe the strengths, limitations, and contemporary use of the different imaging modalities necessary to diagnose prosthetic valve dysfunction.
Patients with a high risk of bleeding undergoing percutaneous coronary intervention (PCI-HBR) were provided consensus-based criteria by the Academic Research Consortium for High Bleeding Risk (ARC-HBR). However, the prognostic predictors in this group of patients have yet to be fully explored. Thus, an effective prognostic prediction model for PCI-HBR patients is required.
We prospectively enrolled PCI-HBR patients from May 2022 to April 2024 at West China Hospital of Sichuan University. The cohort was randomly divided into training and internal validation sets in a ratio of 7:3. The least absolute shrinkage and selection operator (LASSO) regression algorithm was employed to select variables in the training set. Subsequently, a prediction model for 1-year net adverse clinical events (NACEs)-free survival was developed using a multivariable Cox regression model, and a nomogram was constructed. The outcome of the NACEs is defined as a composite endpoint that includes death, myocardial infarction, ischemic stroke, and Bleeding Academic Research Consortium (BARC) grade 3–5 major bleeding. Validation was conducted exclusively using the internal validation cohort, assessing the discrimination, calibration, and clinical utility of the nomogram.
This study included 1512 patients with PCI-HBR, including 1058 in the derivation cohort and 454 in the validation cohort. We revealed five risk factors after LASSO regression, Cox regression, and clinical significance screening. These were then utilized to construct a prognostic prediction nomogram, including chronic kidney disease, left main stem lesion, multivessel disease, triglycerides (TG), and creatine kinase-myocardial band (CK-MB). The nomogram exhibited strong predictive ability (the area under the curve (AUC) to predict 1-year NACE-free survival was 0.728), displaying favorable levels of accuracy, discrimination, and clinical usefulness in the internal validation cohort.
This study presents a nomogram to predict 1-year NACE outcomes in PCI-HBR patients. Internal validation showed strong predictive capability and clinical utility. Future research should validate the nomogram in diverse populations and explore new predictors for improved accuracy.
The data for this study were obtained from the PPP-PCI registry, NCT05369442 (https://clinicaltrials.gov/study/NCT05369442).
Neuromodulation has been shown to increase the efficacy of atrial fibrillation (AF) ablation procedures. However, despite its ability to influence the autonomic nervous system (ANS), the exact mechanism of action remains unclear. The activity of the ANS via the intracardiac nervous system (ICNS) can be inferred from heart rate variability (HRV). Therefore, this study aims to investigate the significance of changes in the ICNS prior to the onset of AF by analyzing the evolution of HRV in a large new cohort of patients.
We selected and annotated recordings with AF and atrial flutter from our database of 95,871 Holter recordings. Each recording included both sinus rhythm and one or more AF episodes. We computed parameters estimating parasympathetic activity (root mean square of successive RR interval differences (RMSSD) and percentage of successive RR intervals that differ by more than 50 ms (pNN50)), as well as HRV frequential parameters a few minutes before AF onset. To allow a minute-by-minute assessment of the parameter changes, we computed their values over 5-minute sliding windows, starting at 35 minutes before AF onset.
The mean age of the whole group of patients was 71.1 ± 11.3 years (range 35–99), the total number of episodes was 1319 on 623 recordings from 570 patients, with an average of 2.1 ± 2.2 episodes per recording (range 1–17) and 2.3 ± 2.6 episodes per patient (range 1–21). The proportion of premature atrial contractions (PACs) increased from 4.8 ± 0.3%, 35 minutes before the onset of AF to 8.3 ± 0.4%, 5 minutes before the AF episode. We measured a statistically significant increase in very-low-frequency (VLF), low-frequency (LF), high-frequency (HF), RMSSD and pNN50 between 35 minutes and 5 minutes before AF onset.
Our data suggest that a significant short-term increase in vagal activity precedes most AF events. Dynamic changes in HRV parameters could be considered when determining the optimal neuromodulation strategies.
Exercise-based cardiac rehabilitation programs (CRP) are recommended for patients following acute coronary syndrome to potentially improve high-density lipoprotein cholesterol (HDL-C) levels and prognosis. However, not all patients reach target HDL-C levels. Here we analyze the dynamics and predictors of HDL-C increase during CRP in patients following ST-segment elevation myocardial infarction or occlusion myocardial infarction.
We conducted a prospective study of myocardial infarction patients who completed exercise-based Phase 2 CRP. Data was collected on clinical variables, cardiovascular risk factors, treatment goals, pharmacological therapy, and health outcomes through questionnaires at the beginning and at the end of Phase 2 CRP. Lipid profile analysis was performed before discharge, 4 to 6 weeks after discharge, and at the end of Phase 2 CRP. Changes in lipid profiles were evaluated, and predictors of failure to increase HDL-C levels were identified by binary logistic regression analysis.
Our cohort comprised 121 patients (mean age 61.67 ± 10.97 years, 86.8% male, and 47.9% smokers before admission). A significant decrease in total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) were noted, along with an increase in HDL-C (43.87 ± 9.18 vs. 39.8 ± 10.03 mg/dL, p < 0.001). Patients achieving normal HDL-C levels (>40 mg/dL in men and >50 mg/dL in women) significantly increased from 34.7% at admission to 52.9% the end of Phase 2. Multivariable analysis revealed smoking history (hazard ratio [HR] = 0.35, 95% confidence interval [CI], 0.11–0.96, p = 0.04), increased reduction in total cholesterol (HR = 0.94, 95% CI, 0.89–0.98, p = 0.004), and increased reduction in LDL-C (HR = 0.94, 95% CI, 0.89–0.99, p = 0.01) were inversely associated with failure to increase HDL-C levels. Conversely, higher HDL-C before CRP (HR = 1.15, 95% CI, 1.07–1.23, p < 0.001) and increased lipoprotein (a) (HR = 1.01, 95% CI, 1–1.02, p = 0.04) predicted failure to increase HDL-C levels. No significant correlations were found with Mediterranean diet adherence, weekly physical activity, training modalities, or physical fitness parameters.
Participation in an exercise-based Phase 2 CRP led to mild but significant increases in HDL-C. Smoking history and patients experiencing substantial reductions in total cholesterol and LDL-C were more likely to experience HDL-C increases, unlike those with higher HDL-C and lipoprotein (a) levels before CRP.
The evolution of left ventricular assist devices (LVADs) from large, pulsatile systems to compact, continuous-flow pumps has significantly improved implantation outcomes and patient mobility. Minimally invasive surgical techniques have emerged that offer reduced morbidity and enhanced recovery for LVAD recipients. Innovations in wireless power transfer technologies aim to mitigate driveline-related complications, enhancing patient safety and quality of life. Pediatric ventricular assist devices (VADs) remain a critical unmet need; challenges in developing pediatric VADs include device sizing and managing congenital heart disease. Advances in LVAD technology adapted for use in right ventricular assist devices (RVADs) make possible the effective management of right ventricular failure in patients with acute cardiac conditions or congenital heart defects. To address disparities in mechanical circulatory support (MCS) access, cost-effective VAD designs have been developed internationally. The Vitalmex device from Mexico City combines pulsatile-flow technology with a paracorporeal design, utilizing cost-effective materials like silicone-elastic and titanium, and features a reusable pump housing to minimize manufacturing and operational costs. Romanian researchers have used advanced mathematical modeling and three-dimensional (3D) printing to produce a rim-driven, hubless axial-flow pump, achieving efficient blood flow with a compact design that includes a wireless power supply to reduce infection risk. In conclusion, MCS continues to advance with technological innovation and global collaboration. Ongoing efforts are essential to optimize outcomes, expand indications, and improve access to life-saving therapies worldwide.
To systematically evaluate risk factors for stress-induced hyperglycemia in patients without diabetes after cardiac surgery.
Databases including CNKI, WanFang data, VIP, SinoMed, PubMed, Web of Science, Embase, and the Cochrane Library were searched using computer retrieval. The data were subjected to an in-depth meta-analysis using RevMan 5.4 and Stata 15.0 software.
This study involved 11,645 postoperative cardiac surgery patients, including 8 case-control studies and 3 cohort studies, over which 18 risk factors were identified. The results of the meta-analysis indicated that statistically significant risk factors included age >65 years [odds ratios (OR) (95% CI ) = 3.47 (2.61–4.32)], female gender [OR (95%) = 1.54 (1.34–1.76)], combined heart valve and coronary artery bypass surgery [OR (95%) = 1.82 (1.23–2.70)], ejection fraction <40% [OR (95%) = 1.38 (1.17–1.63)], history of heart surgery [OR (95%) = 1.30 (1.06–1.59)], myocardial infarction [OR (95%) = 1.17 (1.05–1.31)], hyperlipidemia [OR (95%) = 0.76 (0.67–0.86)], hypertension [OR (95%) = 1.12 (1.03–1.22)], anticoagulant medication [OR (95%) = 0.77 (0.65–0.90)], cardiopulmonary bypass time >2 hours [OR (95%) = 20.26 (17.03–23.48)] and history of cardiopulmonary bypass [OR (95%) = 1.24 (1.09–1.41)].
Current evidence suggests that there are key risk factors for postoperative stress hyperglycemia in patients without diabetes who have undergone cardiac surgery. These factors can help identify patients at a high risk of perioperative stress hyperglycemia during cardiac surgery. This evidence provides a basis for healthcare professionals to develop predictive management strategies for perioperative stress hyperglycemia in patients without diabetes. However, more high-quality studies are required to address the limitations of the current research.
CRD42024479215, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=479215.
Given the close relationship between excessive cortisol secretion and obesity, as well as their intimate associations with cardiometabolic sequelae, this study aimed to evaluate whether elevated cortisol levels and obesity are independently and potentially interactively related to hypertension-mediated organ damage (HMOD) in patients with untreated hypertension.
A total of 936 untreated hypertensive patients were recruited. Body mass index (BMI), 24-hour urinary free cortisol (24 h UFC), and HMOD indicators, including left ventricular hypertrophy (LVH), carotid intima-media thickness (CIMT), and albuminuria, were assessed. Multivariate logistic regression was conducted to evaluate the associations of HMOD indicators with 24 h UFC and obesity. Generalized linear models were used to test for the interaction effects of obesity in the associations between log 24 h UFC levels and HMOD indicators.
Compared to non-obese patients, those who were obese had a greater left ventricular mass index (LVMI), greater CIMT, a higher level of 24-hour urinary albumin (24 h UALB) and more frequent albuminuria (all p < 0.05). In the obese group, elevated 24 h UFC was significantly associated with LVH (odds ratio (OR) = 2.53; 95% CI: 1.02–6.31, p = 0.044) and albuminuria (OR = 3.13; 95% CI: 1.31–7.43, p = 0.01), after multivariate adjusting. There was a significant interactive effect of obesity on the association between 24 h UFC and LVH and albuminuria (all p for interaction <0.05). A significant correlation was observed between 24 h UFC and LVMI in obese and non-obese patients. Conversely, the correlations of 24 h UFC and log 24 h UALB were found only in obese patients but not in non-obese patients.
Elevated 24 h UFC levels were associated with higher severity of HMOD, including more frequent LVH, albuminuria, and greater CIMT. Additionally, obesity modified the effects of 24 h UFC on both LVH and albuminuria.
The substrates for arrhythmias in myocarditis and ischemic heart disease (IHD) are different, but it is yet to be determined whether there is a difference in outcomes following catheter ablation (CA) for ventricular tachycardia (VT) associated with these two conditions. This study aimed to compare outcomes after CA of VT in patients with myocarditis versus those with IHD.
Patients undergoing CA for sustained VT confirmed by endomyocardial biopsy as myocarditis, and patients with IHD experiencing sustained VT undergoing CA were retrospectively enrolled from February 2017 to March 2023. Initially, an endocardial approach was employed, reserving epicardial ablation procedures for non-responders. The primary endpoint was VT recurrence during follow up. All-cause mortality, repeat CA for VT and implantable cardioverter-defibrillator (ICD) implantation served as secondary endpoints. Kaplan-Meier curves compared outcomes between patient groups.
This study included 109 patients with IHD and 20 patients with myocarditis who underwent CA for sustained VT, from February 2017 to March 2023. Compared with IHD patients, myocarditis patients had a statistically significant lower complete short-term success rate of CA (60.0% vs. 85.3%, p = 0.013). During a follow-up period of 37 ± 21 months, 8 (40.0%) myocarditis patients experienced VT recurrence compared to 57 (52.3%) IHD patients, with no statistically significant difference between the two groups. During follow-up, 2 (10.0%) myocarditis patients died and 2 (10.0%) underwent repeat CA for VT recurrence, while 9 (8.3%) IHD patients died, 14 (12.8%) underwent a second CA for VT recurrence, and 8 (7.3%) received an ICD implantation. Additionally, there were no notable variations between the two groups regarding all-cause mortality, repeat CA for VT and ICD implantation.
It was demonstrated that the efficacy of CA in sustained VT in myocarditis patients was similar to that in IHD. For myocarditis patients with VT, CA might be equally effective.
Cardiovascular diseases (CVD) affect around 7.6 million people in the UK, disproportionately affecting the minority ethnic community. In 2009, the UK's National Health Service (NHS) launched a Health Check (NHSHC) scheme to improve early diagnosis of various clinical conditions, including CVD, by screening patients for associated risk factors. This systematic review investigated the engagement of minority ethnic groups with these services.
Seven studies identified patient demographics of NHSHC attendees using the Preferred Reporting Items for Systematic And Meta Analysis-Diagnostic Test Accuracy (PRISMA-DTA) guidelines and accessing Ovid (MEDLINE), PubMed and Web of Science databases.
The screening was either by invitation or opportunistic at other appointments with their doctor. Engagement with the service was highest among the South Asian patients (21%–68%), but lowest amongst Chinese patients (12%–61%). Further, engagement was lower among those screened following a formal invitation than those seen opportunistically. However, a greater proportion of patients were screened opportunistically than by invitation.
Overall, we found that the NHSHC is not being utilised adequately for all patients at high risk of CVD, particularly White and Chinese patients. It highlights the critical role of primary care could play to improve patient engagement with the service.
The relationship between diabetes and heart failure significantly impacts public health. This study assessed the prognostic nutritional index (PNI) as a predictor of heart failure risk in adult diabetic patients.
An analysis was performed on 1823 diabetic adults using data collected from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2016. Serum albumin levels and lymphocyte counts were combined to calculate the PNI. We used descriptive statistics categorized by PNI quartiles and performed multivariate logistic regression to adjust for variables including age, gender, ethnicity, and coexisting medical conditions.
The median age (mean ± SD) was 59.942 ± 12.171 years, and the mean value ± SD of the PNI was 52.412 ± 5.430. The prevalence of heart failure was 7.405%. In the fully adjusted model, for each 1-unit increase in PNI, the risk of heart failure decreased by 8.2% (odds ratio (OR), 0.918; 95% confidence interval (CI) 0.884, 0.953). Participants in the highest PNI quartile (Q4) had a 63% reduced risk of heart failure compared to those in the lowest quartile (Q1). Tests for interactions did not reveal any statistically significant differences among these stratified subgroups (p for interaction > 0.05).
This study demonstrated that a higher PNI was significantly associated with a decreased prevalence of heart failure in adults with diabetes.
Dilated cardiomyopathy (DCM) is the ultimate manifestation of the myocardial response to various genetic and environmental changes and is characterized mainly by impaired left ventricular systolic and diastolic function. DCM can ultimately lead to heart failure, ventricular arrhythmia (VA), and sudden cardiac death (SCD), making it a primary indication for heart transplantation. With advancements in modern medicine, several novel techniques for evaluating myocardial involvement and disease severity from diverse perspectives have been developed. Myocardial fibrosis is a significant contributor to VA events and SCD. Based on different pathological mechanisms, myocardial fibrosis can be categorized into replacement and interstitial forms. Late gadolinium enhancement (LGE) derived from cardiovascular magnetic resonance is the clinical gold standard for evaluating replacement myocardial fibrosis and exhibits high concordance with histological replacement fibrosis. However, because of the absence of normal tissue as a control, the LGE technique often fails to effectively visualize diffuse interstitial fibrosis. In such cases, T1 mapping and extracellular volume fraction mapping can be complementary or alternative methods to the LGE technique for detecting interstitial fibrosis. This review aimed to provide a comprehensive and precise assessment of myocardial fibrosis and to determine the use of cardiac magnetic resonance imaging for prognostic evaluation and risk stratification of patients with DCM.
Tricuspid regurgitation (TR) is a potentially lethal condition and represents a significant clinical challenge both for clinical and interventional cardiologists. Traditionally managed medically and surgically, transcatheter therapies are now an emerging option, especially in patients with prohibitive surgical risk due to age or comorbidities. Transcatheter tricuspid valve replacement (TTVR) is emerging as a potential solution for patients suffering from TR with positive clinical data supporting its use in a wide range of anatomies and clinical settings. However, the adoption of TTVR introduces new challenges, including a scarcity of long-term clinical risks of valve thrombosis, questions regarding the durability of implanted valves, and the potential higher risk for post-procedural pacemaker (PM) implantation.
This study aimed to analyze the metabolic risk factors for microcirculation disorders in patients with unstable angina (UA) after percutaneous coronary intervention (PCI), evaluating their predictive value for developing microcirculation disorders.
A single-center retrospective study design was used, which included 553 patients with UA who underwent PCI. The angiographic microcirculatory resistance (AMR) index was calculated based on coronary angiography data. Patients were divided into two groups according to their post-PCI AMR values: a post-PCI AMR ≤2.50 group and a post-PCI AMR >2.50 group. Variables were included in the multivariate regression model through univariate regression and variance inflation factor (VIF) screening. Subgroup analyses were conducted by sex to further evaluate the predictive value of selected variables in the overall sample. The total sample was randomly split into a 7:3 ratio for the training and validation sets. A nomogram based on the training sets was then constructed to visualize these predictions. The discrimination and calibration of the prediction model were evaluated using the receiver operating characteristic (ROC) curve and calibration curve.
The post-PCI AMR >2.50 group had a higher percentage of females, increased incidence of diabetes, and elevated fasting blood glucose (FBG), glycated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and lipoprotein(a) (Lp(a)) levels (p < 0.05). Logistic regression analysis identified HbA1c, TG, LDL-C, and Lp(a) as independent predictors of elevated AMR post-PCI after adjusting for confounders. Subgroup analysis confirmed no significant interaction between the model and sex (p > 0.05). A nomogram was constructed based on the training set, with the area under the curve (AUC) for the ROC of 0.824 in the training set and 0.746 in the validation set. The calibration curves showed a good fit (training set: p = 0.219; validation set: p = 0.258).
HbA1c, TG, LDL-C, and Lp(a) levels are independent risk factors for microcirculation disorders in patients with UA post-PCI. The constructed nomogram provides good predictive accuracy.
Coronary microvascular dysfunction (CMD) comprises a wide spectrum of structural and/or functional abnormalities of coronary microcirculation that can lead to myocardial ischemia. Emerging evidence has indicated that CMD is a relevant cause of morbidity and mortality and is associated with a high risk of major adverse cardiovascular events (MACEs) and heart failure with preserved ejection fraction as well as poor quality of life. This review aims to elucidate briefly the pathogenesis and diagnostic modalities of CMD and to shed light on contemporary evidence on the prognostic impact of CMD. Finally, we will provide an overview of novel emerging therapeutic strategies for CMD.
The fluorescent dye indocyanine green (ICG) has been used to identify anatomical structures intraoperatively in coronary artery bypass grafting (CABG). This study aimed to evaluate the feasibility of using ICG to assess graft patency and territorial distribution of myocardial reperfusion during CABG.
Porcine arrested hearts (n = 18) were used to evaluate territorial distribution of native coronary arteries and of a coronary bypass constructed with porcine saphenous vein graft (SVG) using ICG. Coronary ostia were dissected and selectively cannulated for ICG injection. Sequential fluorescence was assessed in the epicardial coronary arteries, myocardium and coronary veins using an infrared-sensitive charge-coupled device (CCD) camera system. In a separate set of experiments, SVG was used for anastomosis in end-to-side fashion to a terminal obtuse marginal (OM) branch. This approach was used to avoid bias in the assessment of territorial distribution. The anastomosis was injected with ICG; graft patency and territorial distribution was assessed using an infrared-sensitive CCD camera system from 30 cm above the field, as previously described. Native circulation and SVG grafts were assessed using real-time video recording and fluorescence intensity mapping that was averaged into a graded scoring system. The heart was divided into functional regions: anterior wall, lateral wall, inferior wall and right ventricle. All experiments were performed in triplicates.
After ICG injection into the individual coronary ostia, perfusion of the native coronary artery was visible. Portions of the vessels embedded into the epicardial fat could be easily visualized on the surface of the heart and the dissection facilitated via fluorescence guidance. The territorial distribution reflected the expected regional perfusion. The SVG graft was anastomosed to an OM branch. ICG visualization allowed for assessment of graft patency excluding potential technical anastomosis problems or graft twisting or dissection. The myocardial perfusion observed in real-time confirmed regional distribution to the entire lateral wall and minimally to the inferior wall. These findings were confirmed in all the specimens used in the study.
Besides assisting the identification of intramyocardial vessels, ICG can provide information on the native coronary circulation status and the territorial distribution of the perfusion before and after grafting. It enables visualization of collaterals and the territory of distribution subtended by a graft offering real-time assessment and guidance on the grafting strategy.
Extensive research has established obstructive sleep apnea (OSA) as a contributing factor to numerous cardiovascular and cerebrovascular diseases. However, whether OSA affects in-stent restenosis (ISR) after elective drug-eluting stenting is unclear. Therefore, the objective of this study was to examine the impact of OSA on ISR in patients with coronary heart disease (CHD) who underwent successful elective drug-eluting stent (DES) implantation.
This study retrospectively analyzed CHD patients who successfully underwent elective coronary stent implantation and overnight sleep breathing monitoring and were readmitted for coronary angiography due to symptoms of CHD at 12 to 26 months after percutaneous coronary intervention (PCI). OSA was diagnosed when the apnea-hypopnea index (AHI) was ≥5 events/hour. ISR was defined as >50% restenosis of the vessel diameter in which the DES was implanted. To explore the association between OSA and ISR among patients with CHD, multivariate logistic regression models were developed and utilized.
This study enrolled 206 individuals who were diagnosed with CHD, with a mean age of 62.01 ± 10.27 years, and males constituted 76.2% of the patient population. After a median follow-up period of 15 months following DES implantation, there was a significant increase in the incidence of ISR among patients with moderate to severe OSA, increasing from 10.9% to 31.3% (p < 0.001). According to the fully adjusted model, the occurrence of ISR was found to be independently associated with the presence of OSA (OR: 3.247, 95% CI: 1.373–7.677, p = 0.007).
In individuals who underwent elective drug-eluting stenting, OSA is an independent risk factor for ISR.
Postpartum cardiomyopathy is defined as an incident of acute heart failure in the postpartum period in the absence of any other cause. Up to 10% of postpartum cardiomyopathy may need to undergo heart transplantation later in life. This study aimed to provide a present-day perspective on all-cause mortality and transplant-related complications after heart transplantation for postpartum cardiomyopathy.
A retrospective analysis of the United Network for Organ Sharing (UNOS) registry was performed for adult patients undergoing heart transplants (01/2001–01/2023) for postpartum cardiomyopathy.
A total of 677 patients were identified, with a mean age of 35 years. The mean body mass index (BMI) was 27.2 kg/m2; the most common comorbidity was type 2 diabetes (T2D) (n = 589; 87%). Older age was associated with lower overall mortality (hazard ratio (HR): 0.97; 95% CI: 0.95, 0.98; p < 0.01), while diabetes (HR: 1.01; 95% CI: 1.01, 1.01; p < 0.01), dialysis (HR: 1.01; 95% CI: 1.01, 1.01; p < 0.01), days on Status 1 on the UNOS registry (HR: 1.06; 95% CI: 1.03, 10.9; p < 0.01), creatinine (HR: 1.29; 95% CI: 1.02, 1.64; p = 0.034), and length of stay (HR: 1.01; 95% CI: 1.01, 1.02; p = 0.02) were associated with a higher risk of overall mortality. Moreover, 30-day mortality was 2.8%, and 1-year mortality was 11.1%. The era effect was prominent in cases of 1-year mortality (odds ratio (OR): 0.95; 95% CI: 0.91, 0.99, p = 0.006).
Our results suggest that younger age, diabetes, pretransplant dialysis, days on Status 1, and creatinine are associated with higher mortality, while an era effect was observed for 1-year mortality after heart transplantation (HTx) in patients with postpartum cardiomyopathy.
Hypertension-mediated organ damage (HMOD) is a critical complication of hypertension that can present with cardiac, retinal, and renal manifestations and affect patient outcomes. Serum signal peptide, CUB (complement C1r/C1s, Uegf, and Bmp1) domain, and epidermal growth factor-like domain-containing protein 1 (SCUBE-1), a novel biomarker implicated in vascular pathology, shows promise for detecting HMOD. This study aims to explore the relation between SCUBE-1 levels and HMOD in hypertensive patients.
This cross-sectional study included 115 participants, comprising 79 hypertensive patients and 36 healthy controls. The hypertensive patients were divided into two groups based on HMOD presence. SCUBE-1 levels were measured to evaluate their diagnostic utility in detecting HMOD.
Hypertensive patients exhibited significantly higher SCUBE-1 levels than controls (160.70 ng/mL vs. 75.64 ng/mL, p < 0.001). Among these patients, those with HMOD (cardiac, retinal, and renal) displayed even higher SCUBE-1 levels (311.27 ng/mL, range 137.86–460 ng/mL) compared to those without HMOD (142.53 ng/mL, range 110.56–178.19 ng/mL). Receiver operating characteristic curve analysis indicated that SCUBE-1 levels have significant diagnostic potential for differentiating between hypertensive patients with and without HMOD with area under the curve values of 0.722 for cardiac, 0.761 for retinal, and 0.707 for renal damage.
Our study has revealed that SCUBE-1 levels are significantly elevated in hypertensive patients, particularly those with HMOD. The findings support the potential of SCUBE-1 as a valuable biomarker for predicting organ damage in hypertensive patients.
Hypertension is one of the most prevalent disorders encountered in medical practice, yet effective pharmacotherapy options for resistant hypertension are limited. In this meta-analysis, we aimed to evaluate the efficacy and safety of aprocitentan in treating hypertension.
We searched PubMed, Embase, ClinicalTrials.gov, and the Cochrane Library databases from inception to June 3, 2024, for randomized controlled trials (RCTs) that compared the efficacy and safety between aprocitentan and placebo in treating hypertension. According to the dosage of aprocitentan, the study was divided into a low-dose group (10–12.5 mg), medium-dose group (25 mg), and high-dose group (50 mg).
This meta-analysis included five RCTs, which incorporated 1224 patients, and displayed that aprocitentan can reduce the mean sitting systolic blood pressure (msSBP) [(low dose subgroup: mean difference (MD): –3.85 mmHg; 95% confidence interval (CI): –7.47 to –0.23; p = 0.040; medium dose group: MD: –5.56 mmHg; 95% CI: –10.69 to –0.44; p = 0.030)], mean sitting diastolic blood pressure (msDBP) (low dose subgroup: MD: –3.95 mmHg; 95% CI: –4.06 to –3.85; p < 0.001; medium dose group: MD: –4.75 mmHg; 95% CI: –5.91 to –3.60; p < 0.001), 24-hour ambulatory systolic blood pressure (maSBP) (low dose group: MD: –4.18 mmHg; 95% CI: –4.32 to –4.04; p < 0.001; medium dose group: MD: –5.89 mmHg; 95% CI: –6.03 to –5.75; p < 0.001), and 24-hour ambulatory diastolic blood pressure (maDBP) (low dose group: MD: –4.33 mmHg; 95% CI: –4.42 to –4.24; p < 0.001; medium dose group: MD: –5.82 mmHg; 95% CI: –5.91 to –5.73; p < 0.001). In the high-dose group, there was no difference between the aprocitentan and placebo groups in the msSBP (MD: –4.83 mmHg; 95% CI: –11.44 to 1.79; p = 0.150). Meanwhile, the safety profile of aprocitentan was good, and no significant differences in the frequency of adverse events (AEs) and serious adverse events (SAEs) were observed compared to the placebo.
Aprocitentan significantly reduces blood pressure and has a good safety profile. However, it is worth noting that high doses of aprocitentan (50 mg) did not yield better blood pressure-lowering effects.
Cardiac manifestations in systemic sclerosis (SSc) are variable and are associated with a poor prognosis, frequently resulting in impaired right ventricular function and heart failure. A high proportion of patients with SSc experience pulmonary arterial hypertension (PAH), interstitial lung disease, or myocardial involvement, all of which can lead to exercise intolerance. In this context, cardiopulmonary exercise testing (CPET) is a useful tool for diagnosing exercise intolerance, elucidating its pathophysiology, and assessing its prognosis. CPET can also identify patients with SSc at higher risk of developing PAH. Despite its utility, current guidelines for CPET do not include the evaluation of patients with SSc, nor do standard SSc management guidelines consider CPET in the clinical work-up. This review summarizes the development, supporting evidence, and application of CPET in assessing cardiac involvement in patients with SSc.
Ventricular depolarization refers to the electrical activation and subsequent contraction of the ventricles, visible as the QRS complex on a 12-lead electrocardiogram (ECG). A well-organized and efficient depolarization is critical for cardiac function. Abnormalities in ventricular depolarization may indicate various pathologies and can be present in all leads if the condition is general, or in a subgroup of anatomically contiguous leads if the condition is limited to the corresponding anatomic location of the heart. Furthermore, the assessment of depolarization abnormalities on the ECG may either be identified visually or this may depend on further processing. In recent decades, assessment of depolarization abnormalities has received a lot of attention for cardiac risk stratification. This risk stratification aims to identify patients at high risk of adverse cardiac events, to tailor preventive or therapeutic interventions. In this review, we provide an oversight of different techniques for assessing abnormal ventricular depolarization and their value in diagnosing certain conditions, in risk stratification of adverse events, and in guiding therapeutic decisions. This includes QRS alterations directly corresponding to cardiac conditions, such as bundle branch blocks, or the presence of a delta wave, and also metrics aiming to qualitatively or quantitatively assess myocardial scarring, such as QRS (micro)fragmentation and QRS-scoring, and techniques assessing abnormal late depolarizations, such as signal-averaged ECG. While most established assessments of abnormal depolarization rely on human interpretation and are limited by visual detection, recently introduced analyses, such as QRS micro-fragmentation, aim to tackle these limitations. Besides eliminating bias, these automated analyses bypass the need for human interpretation, thereby paving the way for large population studies.
Breast arterial calcification (BAC) is a common benign finding on a screening mammogram. Additionally, BAC is a type of medial calcification known as Mönckeberg medial calcific sclerosis, which differs from the intimal calcification seen in patients with coronary artery disease (CAD). Recently, BAC has appeared as a new cardiovascular risk stratification method. Studies have indicated a potential link between BAC and cardiovascular risk factors, particularly coronary artery calcification (CAC), as observed in coronary computed tomography. However, the association between BAC and myocardial ischemia and angiographic-proven CAD remains controversial. The usefulness of BAC during mammography as a potential screening tool for CAD has been the subject of uncertainty and debate for many years. This article reviews the current literature on BAC and its association with CAC, myocardial ischemia, and angiographic-proven CAD on both invasive and coronary computed tomography. Cardiovascular outcomes, current limitations, and future investigation and recommendations are also explored and discussed.
Ceramide, a key molecule in sphingolipid metabolism, is recognized as a standalone predictor of long-term major adverse cardiac events (MACE). We explore if integrating the global registry of acute coronary events (GRACE) score with the ceramide risk score (ceramide test 1, CERT1) improves MACE prediction in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
This cohort study included 210 participants with ACS undergoing PCI. MACE was defined as the recurrence of non-fatal acute myocardial infarction, repeat coronary revascularization procedures (PCI or coronary artery bypass grafting, CABG), or death excluding the initial event qualifying the patient for the study. The cumulative incidence of MACE was analyzed using the Kaplan-Meier method. Both univariate and multivariate Cox regression analyses identified MACE predictors. The predictive accuracy of combining the GRACE score with the CERT1 score was assessed using the area under the receiver operating characteristic curve (AUC), integrated discrimination improvement (IDI), and net reclassification improvement (NRI).
During the 12-month follow-up period, 35 of the 210 participants experienced a MACE. The Kaplan-Meier analysis revealed a significant variation in MACE incidence stratified by the CERT1 score (χ2 = 21.344, p < 0.001). Multivariate Cox regression analysis identified low-density lipoprotein (p = 0.002), quantitative flow ratio (p = 0.013), the CERT1 score (p = 0.005), and the GRACE score (p = 0.007) as independent predictors for MACE. Integrating the GRACE score with the CERT1 score improved prediction accuracy, raising the AUC from 0.733 to 0.834. This adjustment provided a more precise risk reclassification and discrimination between patients likely and unlikely to experience MACE (NRI: 0.526, p = 0.004; IDI: 0.120, p < 0.001).
The CERT1 score independently predicts long-term MACE for individuals diagnosed with ACS undergoing PCI. Including the CERT1 score significantly enhances the GRACE score's capacity to risk-stratify these patients.
Registration number: ChiCTR2300068491 (https://www.chictr.org.cn/showproj.html?proj=180370).
This study aimed to develop and validate a predictive model for major depression risk in adult patients with coronary heart disease (CHD), offering evidence for targeted prevention and intervention.
Using data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018, 1098 adults with CHD were included. A weighted logistic regression model was applied to construct and validate a nomogram-based prediction tool for major depression in this population.
The weighted prevalence of major depression among these patients was 13.95%. Multivariate weighted logistic regression revealed that waist circumference, smoking status, arthritis, sleep disorders, and restricted work capacity were independent risk factors for major depression (odds ratio (OR) >1, p < 0.05). The areas under the receiver operating characteristic (ROC) curve in the nomogram model for both the development and validation cohorts were 0.816 (95% confidence interval (CI): 0.776–0.857) and 0.765 (95% CI: 0.699–0.832), respectively, indicating the model possessed strong discriminative ability. Brier scores in the development and validation cohorts were 0.107 and 0.127, respectively, both well below the 0.25 threshold, demonstrating good calibration. Decision curve analysis (DCA) showed that when the threshold probability for major depression ranged from 0.04 to 0.54 in the development group and from 0.08 to 0.52 in the validation group, the nomogram provided the highest clinical net benefit compared to “Treat All” and “Treat None” strategies, confirming its strong clinical utility.
With a weighted prevalence of 13.95%, this nomogram model shows excellent predictive performance and clinical relevance for predicting major depression risk in patients with CHD. Thus, the model can be applied to aid healthcare professionals in identifying high-risk individuals and implementing targeted preventive strategies, potentially lowering the incidence of major depression in this patient population.
Aspirin treatment is recommended as a secondary prevention strategy and could be a potential primary prevention strategy for cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). However, aspirin resistance is notably common among diabetic patients, compromising the efficacy of aspirin treatment. Hence, our study sought to assess the clinical predictors of aspirin resistance (AR) in T2DM patients.
We conducted a systematic search of three major medical databases (PubMed, Embase, and Cochrane Library) to identify relevant articles up to September 17, 2024. Details of publications and investigated parameters were extracted from the selected studies. The meta package in the R language software was utilized to synthesize the evidence concerning clinical predictors of AR. We applied either a fixed- or random effects model based on the heterogeneity observed among the included studies. The pooled results were visually displayed using forest plots.
In total, 10 publications were finally included in our study (n = 2113 patients). AR was predominantly linked to specific laboratory parameters, particularly those indicative of heightened insulin resistance and inadequate lipid management. Specifically, the laboratory parameters associated with AR included fasting glucose level (mean difference (MD) = 8.21; 95% confidence interval (CI) = 2.55 to 13.88), glycated hemoglobin (MD = 0.22; 95% CI = 0.06 to 0.38), high-density lipoprotein (HDL) level (MD = –2.02; 95% CI = –3.62 to –0.42), low-density lipoprotein (LDL) level (MD = 7.00; 95% CI = 2.87 to 11.13), total cholesterol level (MD = 9.52; 95% CI = 4.37 to 14.67), and triglyceride levels (MD = 12.51; 95% CI = 3.47 to 21.55).
Markers associated with dyslipidemia and blood glucose levels are robust indicators of AR in individuals with T2DM. These findings imply that assessing lipid and glucose regulation could enhance the development of personalized preventive approaches for vascular complications linked to diabetes.
CRD42023388170, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=388170
Inherited cardiac arrhythmias, which may lead to sudden cardiac death, represent a significant health risk, with genetic factors playing a key role in their development. The ankyrin 2 (ANK2) gene, encoding ankyrin-B, is implicated in several heritable arrhythmia syndromes. ANK2 variants have been linked to an inherited condition known as “ankyrin-B syndrome”, which manifests as a spectrum of cardiac arrhythmias and cardiomyopathy. Our current review examines the relationship between ANK2 variants and specific heart conditions, summarizing recent findings on the genetic and molecular mechanisms underlying ANK2-related arrhythmias and structural abnormalities. By emphasizing the need for further research, this review aims to enhance understanding of ANK2’s role in heart disease and guide the development of effective therapies.
This article focuses on the effect of body mass index (BMI) on cardiac structure and function in cases with non-valvular atrial fibrillation (NVAF). Only a few articles have investigated the relationship between BMI and the incidence of left atrial thrombus (LAT) or spontaneous echo contrast (SEC) in cases with NVAF.
This single-center retrospective study was conducted at The First People's Hospital of Changzhou. A total of 282 patients who were diagnosed with NVAF and planned to undergo radiofrequency ablation from 2019 to 2022 were enrolled in this study. None of the patients received standardized anticoagulant therapy. The patients were divided into a normal weight group, an overweight group, and an obesity group based on their BMI. The differences in echocardiographic parameters and LAT/SEC incidences among the three groups were compared, and regression analysis was applied to determine the correlation between BMI and the occurrence rates of LAT/SEC. The generalized additive model (GAM) was used to clarify the dose-response association between BMI and LAT/SEC.
Left atrial diameter (LAD), left ventricular end-diastolic diameter (LVEDD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular ejection fraction (LVEF), right atrial diameter (RAD), and the incidences of LAT/SEC were statistically different among the three groups. Univariate and multivariate logistic regression analyses indicated that BMI was related to the incidences of LAT/SEC. For each 1-unit increase in BMI, the odds of LAT/SEC increased by 12% (odds ratio (OR): 1.12, 95% CI: 1.02, 1.24). A threshold nonlinear relationship was found using the GAM between BMI and the risk of LAT/SEC.
BMI significantly affects multiple echocardiographic parameters in patients with NVAF, and BMI is an independent risk factor for LAT/SEC in cases with NVAF.
To compare the efficacy and safety of novel oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in nonvalvular atrial fibrillation (NVAF) patients with left atrial/left atrial thrombosis through a systematic review and meta-analysis.
The CBM (China Biology Medicine disc), CNKI (China National Knowledge Infrastructure), VIP (Chinese Technology Periodical Database), Wanfang, PubMed, Embase, Cochrane Library, and Web of Science databases were searched for relevant studies from their inception to June 30, 2022.
Twelve articles (eight cohort studies and four randomized controlled trials) involving 982 patients were included. Meta-analysis showed that NOACs had a significantly higher thrombolysis rate than VKAs (78.0% vs. 63.5%, odds ratio (OR) = 2.32, 95% confidence interval (CI) 1.71 to 3.15, p < 0.0001). Subgroup analysis revealed rivaroxaban to be more effective than VKAs, whereas there was no significant difference between dabigatran and apixaban. There were no significant differences in embolic events, bleeding, or all-cause mortality. Thrombus resolution analysis showed higher left ventricular end-diastolic diameter and smaller left atrial diameter in the effective group than in the ineffective group.
NOACs are more effective in thrombolysis than VKAs in NVAF patients with left atrial thrombosis, and there is no increased risk of adverse events compared with VKAs.
Studies using machine learning to identify the target characteristics and develop predictive models for coronary artery disease severity in patients with premature myocardial infarction (PMI) are limited.
In this observational study, 1111 PMI patients (≤55 years) at Tianjin Chest Hospital from 2017 to 2022 were selected and divided according to their SYNTAX scores into a low-risk group (≤22) and medium–high-risk group (>22). These groups were further randomly assigned to a training or test set in a ratio of 7:3. Lasso–logistic was initially used to screen out target factors. Subsequently, Lasso–logistic, random forest (RF), k-nearest neighbor (KNN), support vector machine (SVM), and eXtreme Gradient Boosting (XGBoost) were used to establish prediction models based on the training set. After comparing prediction performance, the best model was chosen to build a prediction system for coronary artery severity in PMI patients.
Glycosylated hemoglobin (HbA1c), angina, apolipoprotein B (ApoB), total bile acid (TBA), B-type natriuretic peptide (BNP), D-dimer, and fibrinogen (Fg) were associated with the severity of lesions. In the test set, the area under the curve (AUC) of Lasso–logistic, RF, KNN, SVM, and XGBoost were 0.792, 0.775, 0.739, 0.656, and 0.800, respectively. XGBoost showed the best prediction performance according to the AUC, accuracy, F1 score, and Brier score. In addition, we used decision curve analysis (DCA) to assess the clinical validity of the XGBoost prediction model. Finally, an online calculator based on the XGBoost was established to measure the severity of coronary artery lesions in PMI patients
In summary, we established a novel and convenient prediction system for the severity of lesions in PMI patients. This system can swiftly identify PMI patients who also have severe coronary artery lesions before the coronary intervention, thus offering valuable guidance for clinical decision-making.
Out-of-hospital cardiac arrest (OHCA) is a leading cause of death worldwide, with a low survival rate of around 7% globally. Key factors for improving survival include witnessed arrest, bystander cardiopulmonary resuscitation (CPR), and early defibrillation. Despite guidelines advocating for the “chain of survival”, bystander CPR and defibrillation rates remain suboptimal. Innovative approaches, such as dispatcher-assisted CPR (DA-CPR) and smartphone-based alerts, have emerged to address these challenges. DA-CPR effectively transforms emergency callers into lay rescuers, and smartphone apps are increasingly being used to alert volunteer first responders to OHCA incidents, enhancing response times and increasing survival rates. Smartphone-based systems offer advantages over traditional text messaging by providing real-time guidance and automated external defibrillator (AED) locations. Studies show improved outcomes with app-based alerts, including higher rates of early CPR, increased survival rates and improved neurological outcomes. Additionally, the potential of unmanned aerial vehicles (drones) to deliver AEDs rapidly to OHCA sites has been demonstrated, particularly in rural areas with extended emergency medical services response times. Despite technological advancements, challenges such as ensuring responder training, effective dispatching, and maintaining responder well-being, particularly during the coronavirus disease 19 (COVID-19) pandemic, remain. During the pandemic, some community first responder programs were suspended or modified due to shortages of personal protective equipment (PPE) and increased risks of infection. However, systems that adapted by using PPE and revising protocols generally maintained responder participation and effectiveness. Moving forward, integrating new technology within robust responder systems and support mechanisms will be essential to improving OHCA outcomes and sustaining effective response networks.
Lipoprotein(a) (Lp(a)) serum concentration plays a crucial role as a risk factor in cardiovascular diseases and is gaining more and more attention. Patients with elevated lipoprotein(a) levels are often prescribed statins as they also have high concentrations of low-density lipoprotein cholesterol (LDL-C). Statins are drugs that successfully decrease LDL-C, but their effectiveness in Lp(a) levels reduction is uncertain. The aim of this study was to evaluate if statin therapy can affect Lp(a) concentration. A literature search on databases like PubMed, Oxford Academic, ScienceDirect, Embase, The Cochrane Library, Scopus, and Springer Link was conducted from 1 May to 10 August 2024 with the aim of finding studies concerning the effect of statins on Lp(a) levels. Only randomised control studies and studies with a placebo/comparator arm were included. For calculations, SPSS Statistics software version 29 was used. The risk of bias for this study was assessed using the revised Cochrane risk-of-bias tool for randomised trials. Overall, 43 studies (13,264 participants in study arms and 11,676 in control arms) were included in the analysis. The mean difference of absolute change in Lp(a) concentration for all 43 studies equaled 0.22 mg/dL and was not clinically significant. Egger's regression-based test resulted in no risk of bias in this study (p = 0.404). In conclusion, statin therapy does not significantly affect Lp(a) levels. Results of this work suggest that people with high Lp(a) levels will not change their Lp(a)-associated cardiovascular (CV) risk by statin administration.
Right ventricular (RV) pacing exacerbates heart failure and increases cardiac mortality in patients with reduced ejection fraction (EF). However, its impact on left ventricular dysfunction in patients with preserved EF remains inconclusive. This study investigates the relationship between RV pacing, global longitudinal strain (GLS), and EF in patients with preserved EF.
This prospective registry study included patients with preserved EF (≥50%) undergoing de novo permanent pacemaker (PPM) implantation for atrioventricular block at Chosun University Hospital, South Korea, from 2018 to 2022. Echocardiographic evaluations were performed pre-implant, post-implant, and at 12 months, with follow-up visits every 3–6 months. Composite outcomes included cardiac death, heart failure hospitalization, pacing-induced cardiomyopathy (PICM), and biventricular pacing (BVP) upgrade.
A total of 71 patients (28 males, mean age 73.1 years) were included. Following PPM implantation, significant declines in both EF and GLS were noted, especially in those with PICM. Over three years, 2 patients died, 6 were hospitalized, 7 developed PICM, and 3 underwent a BVP upgrade. Reduced post-implant GLS was an independent predictor of PICM (hazard ratios (HR) 1.715, 95% CI 1.174–2.504; p = 0.005). Receiver operating characteristic (ROC) analysis showed an area under curve (AUC) of 0.92 for GLS, with a GLS <–15.0 having 100% sensitivity and 80.9% specificity for predicting PICM.
Post-implant GLS is a reliable predictor of PICM in patients with preserved EF. Regular GLS monitoring can guide timely interventions, including guideline-directed medical therapy or BVP upgrades, to prevent deterioration and improve outcomes.
Prognosis assessments for transcatheter aortic valve implantation (TAVI) patients remain challenging, particularly as the indications for TAVI expand to lower-risk patients. This study assessed the prognostic value of the tricuspid regurgitation impact on outcomes (TRIO) score in patients after TAVI.
This single-center study included 530 consecutive patients who underwent TAVI. Patients with a TRIO score >4 were compared to those with a score ≤4. The primary outcome was all-cause mortality, while secondary outcomes included complications defined by the Valve Academic Research Consortium 2 (VARC-2) criteria and major adverse cardiovascular events (MACEs), including mortality, stroke, and heart failure rehospitalization.
Over a mean follow-up period of 22 months, patients with a TRIO score >4 had significantly higher rates of mortality (11.5% vs. 3.1%, p < 0.001) and MACEs (14.9% vs. 3.6%, p < 0.001). Multivariable Cox regression analysis identified a TRIO score >4 as an independent risk factor for all-cause mortality (hazard ratio (HR): 2.41, 95% confidence interval (CI): 1.08–5.37, p = 0.032) and MACEs (HR: 2.78, 95% CI: 1.34–5.75, p = 0.006). Patients with a higher TRIO score also had significantly higher rates of stroke (3.1% vs. 0.5%, p = 0.028), acute kidney injury (10.1% vs. 4.3%, p = 0.011), and MACEs (14.9% vs. 3.6%, p < 0.001) within 30 days after TAVI.
The TRIO score was associated with all-cause mortality and MACEs in patients after a TAVI. The TRIO score could serve as a convenient tool for risk stratification in clinical practice, aiding in identifying high-risk patients.